News

Bristol-Myers Squibb and Alder Biopharmaceuticals have entered into a global agreement for the development and commercialisation of ALD518. ALD518 is a novel biologic that has completed Phase IIa

The US Department of Veterans Affairs (VA) has awarded a $1.84m grant to Diamyd, a wholly-owned subsidiary of Diamyd Medical, to support the development of Nerve Targeting Drug

Sanofi-aventis and Regeneron Pharmaceuticals (Regeneron) have entered into agreements to expand and extend their existing global collaboration to discover, develop, and commercialise fully-human therapeutic monoclonal antibodies. Both the

Catalyst Pharmaceutical (Catalyst) has reported that a team of neuroscientists at The Feinstein Institute for Medical Research at North Shore-Long Island Jewish Health System (LIJ) has received a

Sigma-Aldrich has entered into an exclusive worldwide distribution agreement with Stemgent, to offer Stemgent’s portfolio of lentivirus-based delivery systems for the generation of induced pluripotent stem (iPS) cells.

Immunovaccine has signed a collaborative agreement with the National Cancer Institute (NCI) in Maryland, US. The research collaboration involves formulating NCI’s cancer vaccine antigens in DepoVax, Immunovaccine’s vaccine

Lubrizol has appointed Edward Campbell to its board of directors. Mr. Campbell is chairman, president and CEO of Nordson Corporation. Mr. Campbell spent 11 years in operating and

ImmuneRegen has reported positive results from a study that evaluated its lead anti-Influenza drug, Homspera. The study in animals infected with H5N1 (Avian) Influenza virus, revealed that Homspera

GlaxoSmithKline (GSK) and Genmab’s antibody Arzerra, which has been approved for use in patients with chronic lymphocytic leukemia (CLL) by the US Food and Drug Administration (FDA), will